CD274 and non-small cell lung carcinoma: Reck et al. 53 pointed out that in advanced NSCLC patients, pembrolizumab significantly prolonged progression-free survival and overall survival with fewer adverse events compared to platinum-based chemotherapy when PD-L1 was expressed in at least 50% of tumor cells.